Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

Summary

Treatments for COVID-19 are urgently needed. Emricasan (EMR) is a pan caspase inhibitor. Caspase-1 plays a role in a form of cell death called pyroptosis. EMR inhibits pyroptosis. The Investigators have shown that peripheral blood lymphocytes of COVID-19 patients overexpress caspase-1, providing evidence for pyroptosis. A recent European study corroborate the Investigators finding as they have shown evidence for the activation of the inflammasome in COVID-19.

Timeline

Start

2021-03-11

Primary completion

2021-05-28

Completion

2021-05-28

Outcome

Outcome not reported

Stopped (Enrollment): “Unforeseeable difficulties in recruiting patients. There were no reported serious adverse events.”

Drugs

Indications